Get the Stockscreener App
72.89
0.01%
-0.01
After Hours:
72.89
Avidity Biosciences Inc stock is traded at $72.89, with a volume of 1.85M.
It is down -0.01% in the last 24 hours and up +0.72% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$72.90
Open:
$72.81
24h Volume:
1.85M
Relative Volume:
0.76
Market Cap:
$11.26B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-20.49
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
+0.21%
1M Performance:
+0.72%
6M Performance:
+57.46%
1Y Performance:
+108.73%
1-Day Range:
$72.80
$72.95
1-Week Range:
$72.64
$73.06
52-Week Range:
$21.51
$73.06
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.89 | 11.26B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences prices $600M stock offering - MSN
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Avidity Biosciences (RNA) - The Globe and Mail
(RNA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Key facts: JPMorgan raises concerns on Novartis outlook; Novartis to acquire Avidity - TradingView
Avidity Biosciences Announces Expected Record Date for Spin-Off - TradingView
Avidity Biosciences stock hits all-time high at 72.74 USD By Investing.com - Investing.com Australia
Avidity Biosciences receives FTC clearance for Novartis merger - MSN
Novartis (NVS) Acquisition of Avidity Biosciences Moves Forward - GuruFocus
Avidity Biosciences Sets February 15, 2026 as Record Date for Planned Spin-Off - geneonline.com
Avidity holders to get Atrium cardiology SpinCo shares in Novartis deal - stocktitan.net
Avidity Biosciences says record date set for February 12, 2026 for spin-off - marketscreener.com
Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off - TradingView
Avidity Biosciences Announces Share Distribution for Spin-Off - intellectia.ai
Avidity Biosciences (NASDAQ:RNA) Hits New 12-Month HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at 72.74 USD - Investing.com
New York State Common Retirement Fund Purchases 120,365 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Atle Fund Management AB Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
Halper Sadeh LLC Encourages TWO, RNA, CVBF, TBN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Avidity Biosciences Sets February Vote on $72-per-Share Novartis Takeover and Cardiology Spin-Off - TipRanks
Risk Recap: Whats the fair value of Avidity Biosciences Inc stock2025 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
Price Action: Will Avidity Biosciences Inc announce a stock splitJuly 2025 Decliners & Growth Focused Stock Reports - baoquankhu1.vn
Mutual of America Capital Management LLC Trims Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
EFG Asset Management North America Corp. Reduces Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences, Inc. (RNA) Stock Analysis: A Biotech Powerhouse with 434% Revenue Growth and Promising Clinical Trials - DirectorsTalk Interviews
Aug Momentum: Will Avidity Biosciences Inc outperform tech stocksJuly 2025 Review & Stepwise Trade Execution Plans - baoquankhu1.vn
Avidity Biosciences CSO sells $473k in RNA stock By Investing.com - Investing.com South Africa
Avidity Biosciences CFO MacLean sells $329k in stock By Investing.com - Investing.com Australia
Avidity Biosciences CMO sells $354k in stock By Investing.com - Investing.com South Africa
Avidity Biosciences Insider Sold Shares Worth $473,388, According to a Recent SEC Filing - 富途资讯
Avidity Biosciences CEO Boyce sells $1.04 million in stock By Investing.com - Investing.com Canada
Avidity Biosciences (NASDAQ:RNA) Insider Sells $473,388.30 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Insider Sells $354,642.75 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) CEO Sells $1,042,338.15 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Insider Teresa Mccarthy Sells 2,929 Shares - MarketBeat
Avidity Biosciences CMO sells $354k in stock - Investing.com
Avidity Biosciences CSO sells $473k in RNA stock - Investing.com
Avidity Biosciences stock hits all-time high at $72.70 By Investing.com - Investing.com Australia
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at $72.70 - Investing.com
Weekly Earnings: Can Kosmos Energy Ltd expand into new marketsQuarterly Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Retail Trends: Is Avidity Biosciences Inc a cyclical or defensive stockJuly 2025 Rallies & Low Volatility Stock Recommendations - baoquankhu1.vn
Avidity reports FTC granted request for early termination of HSR waiting period - MSN
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring the Biotech Firm’s 434% Revenue Growth and Future Prospects - directorstalkinterviews.com
Avidity Biosciences CFO sells $93,985 in stock - MSN
Can Avidity Biosciences Inc continue delivering strong returnsTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
Aug PostEarnings: Can Avidity Biosciences Inc outperform in the next rallyJuly 2025 Volume & AI Driven Stock Price Forecasts - baoquankhu1.vn
Avidity Biosciences (NASDAQ:RNA) Hits New 1-Year HighHere's What Happened - MarketBeat
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
7.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):